Literature DB >> 9459321

Thrombophilic genotypes in subjects with idiopathic antiphospholipid antibodies--prevalence and significance.

P R Ames1, C Tommasino, G D'Andrea, L Iannaccone, V Brancaccio, M Margaglione.   

Abstract

To evaluate the significance of common thrombophilic genotypes in subjects with idiopathic antiphospholipid antibodies (aPL) we determined the methylenetetrahydrofolate reductase C677-->T (MTHFR) and factor V A506-->G (FV Leiden) polymorphisms in 49 subjects with idiopathic aPL (57% of whom suffered spontaneous vein thrombosis), in 70 subjects with a history of spontaneous vein thrombosis and in 193 healthy subjects. The prevalence of MTHFR C677-->T+/+ (homozygotes) was 25%, 18% and 17% respectively amongst aPL thrombotics, non aPL thrombotics and controls and that of MTHFR C677-->T+/- (heterozygotes) was 53%, 59% and 53% respectively in the same groups. The prevalence of FV Leiden was higher in aPL thrombotics (14%) and in non aPL thrombotics (18%) than in controls (4%) (p < or = 0.05). APL thrombotics with MTHFR C677-->T+/+ had a lower mean age at first thrombotic event (22 +/- 6 years) than aPL thrombotics with MTHFR C677-->T+/- and non mutated considered together (38 +/- 14 years, p = 0.0004) and than non aPL thrombotics with MTHFR C677-->T+/+ (38 +/- 14 years, p = 0.003). FV Leiden may contribute to the hypercoagulability of a small, albeit significant proportion of thrombotic aPL subjects, whereas the association between MTHFR C677-->T+/+ and aPL may have an impact on age at first occlusive event and suggests a possible pathogenetic interaction.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9459321

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  10 in total

1.  Antiphospholipid antibodies in systemic sclerosis: a double oxidative hit?

Authors:  Paul R J Ames
Journal:  Clin Rheumatol       Date:  2009-06-10       Impact factor: 2.980

Review 2.  What causes the antiphospholipid syndrome?

Authors:  J T Merrill
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

Review 3.  What is antiphospholipid syndrome?

Authors:  Doruk Erkan; Michael D Lockshin
Journal:  Curr Rheumatol Rep       Date:  2004-12       Impact factor: 4.592

Review 4.  Genetics of antiphospholipid syndrome.

Authors:  Tetsuya Horita; Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2004-12       Impact factor: 4.592

5.  Juvenile patients with the homozygous MTHFR C677T genotype develop ischemic stroke 5 years earlier than wild type.

Authors:  Paul R J Ames; Giovanna D'Andrea; Vincenzo Marottoli; Alessia Arcaro; Luigi Iannaccone; Fabrizio Gentile; Maurizio Maraglione
Journal:  J Thromb Thrombolysis       Date:  2022-08-02       Impact factor: 5.221

6.  Liver Cirrhosis Patients Homozygous for MTHFR C677T Develop Portal Vein Thrombosis 8 Years Earlier Than Wild Type.

Authors:  Paul R J Ames; Giovanna D'Andrea; Alessia Arcaro; Vincenzo Marottoli; Luigi Iannaccone; Maurizio Maraglione; Fabrizio Gentile
Journal:  Dig Dis Sci       Date:  2022-08-24       Impact factor: 3.487

7.  Thrombophilia and damage of kidney during pregnancy.

Authors:  Larciprete Giovanni; Liumbruno Giancarlo Maria; Rongioletti Mauro; Montagnoli Carlotta; Rossi Federica; Papa Fabrizio; Jarvis Sheba; Di Pierro Giuseppe; Bompiani Alessandro; Cirese Elio; Valensise Herbert
Journal:  J Prenat Med       Date:  2011-10

Review 8.  The prevalence and clinical significance of inherited thrombophilic risk factors in patients with antiphospholipid syndrome.

Authors:  Reyhan Diz-Kucukkaya; Veysel Sabri Hancer; Bahar Artim-Esen; Yuksel Pekcelen; Murat Inanc
Journal:  J Thromb Thrombolysis       Date:  2010-04       Impact factor: 2.300

9.  Factor V Leiden and thrombosis in patients with systemic lupus erythematosus: a meta-analysis.

Authors:  R Kaiser; J L Barton; M Chang; J J Catanese; Y Li; A B Begovich; L A Criswell
Journal:  Genes Immun       Date:  2009-05-07       Impact factor: 2.676

10.  Thrombophilias and pregnancy complications: a case-control study.

Authors:  Larciprete Giovanni; Angelucci Piero Antonio; Celleno Danilo; Gioia Stefano; Deaibess Therese; Romanini Maria Elisabetta; Brienza Letizia; Cirese Elio; Arduini Domenico
Journal:  Int J Biomed Sci       Date:  2007-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.